JPS6318961B2 - - Google Patents
Info
- Publication number
- JPS6318961B2 JPS6318961B2 JP57025440A JP2544082A JPS6318961B2 JP S6318961 B2 JPS6318961 B2 JP S6318961B2 JP 57025440 A JP57025440 A JP 57025440A JP 2544082 A JP2544082 A JP 2544082A JP S6318961 B2 JPS6318961 B2 JP S6318961B2
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- molecular weight
- molecular
- gel
- molecular sieve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000004676 glycans Chemical class 0.000 claims description 57
- 229920001282 polysaccharide Polymers 0.000 claims description 57
- 239000005017 polysaccharide Substances 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 235000013500 Melia azadirachta Nutrition 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 239000002808 molecular sieve Substances 0.000 claims description 21
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 230000000259 anti-tumor effect Effects 0.000 claims description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 238000002523 gelfiltration Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000000862 absorption spectrum Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000003349 gelling agent Substances 0.000 claims description 8
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims description 6
- 229920001503 Glucan Polymers 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 238000005227 gel permeation chromatography Methods 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 239000005373 porous glass Substances 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 3
- 240000005343 Azadirachta indica Species 0.000 claims 2
- 238000007873 sieving Methods 0.000 claims 2
- 244000237986 Melia azadirachta Species 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 24
- 238000000034 method Methods 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 15
- 206010003445 Ascites Diseases 0.000 description 12
- 208000006268 Sarcoma 180 Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- -1 gel filtration Chemical compound 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Description
【発明の詳細な説明】
発明の背景
技術分野
本発明は新規な抗腫瘍性多糖体およびその製造
法に関する。
さらに詳しくは、本発明はニーム樹皮の熱水抽
出液を精製して得られる抗腫瘍性中性多糖体およ
びその製造法に関するものである。本発明の多糖
体は癌の治療薬として有用である。
先行技術
従来ニーム抽出物が種々な薬理作用を有するこ
とは知られている。即ち、ニームの樹皮、葉部、
花部、果実、枝部、根皮または樹脂を水または親
水性溶媒で抽出するかあるいは微粉砕して皮膚化
粧料を得る方法(特公昭52−28853、同52−28854
および53−10125)、上記ニーム原料を親水性溶媒
および(または)熱水で抽出して抗菌作用、胃
腸・肝臓機能改善作用を有する成分を得る方法
(特公昭53−10124)および上記ニーム原料を疎水
性溶媒で抽出して皮膚疾患およびリユウマチの治
療に有効な成分を得る方法(特公昭53−13689)
が報告されている。
本発明者等は先にニーム樹皮の熱水抽出物が細
胞分裂阻止活性を有することを見い出したが、さ
らに研究を進めた結果、ニーム樹皮熱水抽出物の
薬理活性成分としてα−(1→4)−グルカンの主
鎖にアラビノースがα−(1→6)結合し、グル
コースとアラビノースの構成割合が約5:1であ
る中性多糖体を単離した。この多糖体は文献未載
の新規化合物であつて優れた抗腫瘍作用を有す
る。
発明の目的
従つて本発明の目的は、制癌剤として有用な上
記多糖体を提供することにある。本発明の多糖体
は後述する如く、ザルコーマ180腹水型および固
形型マウス移植腫瘍に対して強い抑制活性を示
し、特に定着固形腫瘍に対して著効を示す。
本発明の目的はさらに上記多糖体を製造する方
法を提供することにある。本発明の方法によれ
ば、上記多糖体は、ニーム樹皮の熱水抽出液を分
子篩処理、特にゲル過し分子量約94000の化合
物を採取することによつて製造される。
発明の具体的説明
本発明は第1に、ニーム樹皮より得られる下記
構造および特性を有する抗腫瘍性多糖体からな
る。
(イ) 構造
α−(1→4)−グルカンの主鎖にアラビノー
スがα−(1→6)結合し、グルコースとアラ
ビノースの構成割合が約5:1の中性多糖体。
(ロ) 色と形状
凍結乾燥品は白色粉末である。
(ハ) 溶解性
水に可溶で、メタノール、エタノール、アセ
トン、エーテル、クロロホルム、酢酸エチル、
ベンゼンおよびヘキサン等の有機溶媒に不溶で
ある。
(ニ) 呈色反応
フエノール硫酸反応、アンスロン硫酸反応に
陽性でヨウ素の添加により青緑色を呈する。
(ホ) 分子量
分画分子量1×103〜2×105の分子篩剤を用
いたカラムゲルクロマトグラフイで単一のピー
クを与え、分子量は約94000である。
(ヘ) 比旋光度
〔α〕22 D:−35゜(c=0.4、H2O)
(ト) 赤外線吸収スペクトル
第1図に示す通りである。
IRνKBr naxcm-1:3400、2930、1620
(チ) 紫外線吸収スペクトル
水溶液中の測定で吸収極大を示さず、末端吸
収のみを示す。
(リ) 13C核磁気共鳴スペクトル
重水中で外部基準にTMS(テトラメチルシラ
ン)を使用して測定した100MHz 13C核磁気共
鳴スペクトルは第2図の通りである。
δppm:108.9、101.1、74.8、72.9、62.1
本発明は第2に、ニーム樹皮の熱水抽出液を分
子篩処理し、分子量約94000を有する化合物を採
取してなる上記抗腫瘍性多糖体の製造法からな
る。
本発明は第3に、上記分子篩処理として先ず分
画分子量約1×103〜1×105乃至1×103〜2×
105の分子篩剤を用いて行ない、次いで最初の多
糖体画分をさらに分画分子量約1×103〜2×105
乃至1×103〜8×105の分子篩剤を用いて行な
い、最初の多糖体画分を採取してなる上記抗腫瘍
性多糖体の製造法からなる。
本発明は第4に、上記分子篩処理がゲル過で
あり、上記分子篩剤がゲル過剤である上記抗腫
瘍性多糖体の製造法からなる。
本発明は第5に、上記ゲル過剤がデキストラ
ンゲル、ポリアクリルアミドゲル、親水性ポリビ
ニル系ゲルまたは多孔性ガラスビーズである上記
抗腫瘍性多糖体の製造法からなる。
本発明の方法を実施するに際しては、ニーム樹
皮の熱水抽出液を分子篩処理、特にゲル過し、
分子量約94000を有する化合物を採取する。
本発明方法の原料植物であるニームは学名をメ
リア・アザジラクタ(Melia azadirachta)とい
い、熱帯地域に自生する高さ10m以上に達する木
本植物である。本発明の方法においては、ニーム
の樹皮の熱水抽出液を原料として使用する。ニー
ム樹皮を熱水で抽出処理する操作は常法に従つて
行なわれる。即ち、細断したニーム樹皮に熱水を
加えるか、あるいは、ニーム樹皮に水を加え、そ
の混合物を加熱沸騰させることによつて実施され
る。加熱は沸騰水浴中または直火で行うことがで
きる。抽出時間は原料の品質等に従つて適宜決定
されるが通常1乃至48時間である。抽出終了後、
抽出混合物を過することにより抽出液が得られ
る。かくして得られたニーム樹皮熱水抽出液には
多量の不純物が含まれているので本発明のゲル
過工程に供する前に、アルコール沈澱法または透
析膜法により、該抽出液を精製するのが望まし
い。例えば、アルコール沈澱法で精製する場合に
は、上記抽出液にメタノール、エタノールのよう
なアルコールを加え、生成した沈澱を常法によ
り、例えば遠心分離により採取する。透析膜法に
より精製する場合は、該抽出液を透析膜に入れ、
水につけて透析し、透析内液を所望により濃縮乾
固するかまたは凍結乾燥して抽出物を得る。透析
膜としては分画分子量50000以下のもの、例えば
スペクトラ・ポア1〜6(スペクトラム・メデイ
カル・インダストリーズ社製品)、ビスキング・
チユーブ(ユニオンカーバイト社製品)が使用さ
れる。アルコール沈澱法または透析膜法で精製し
て得られた抽出物を水に溶解して本発明方法の原
料であるニーム樹皮熱水抽出液とする。さらに、
ニーム樹皮の熱水抽出処理に先立つて、ニーム樹
皮を有機溶媒および(または)常温の水で抽出前
処理することにより、不要成分を予め除去してお
くことも望ましい。抽出前処理に使用する溶媒と
してはメタノール、エタノール、プロパノール、
ピリジン、アセトンのような極性有機溶媒、ベン
ゼン、トルエン、キシレン、n−ヘキサン、クロ
ロホルム、四塩化炭素、酢酸エチルのような非極
性有機溶媒があげられる。
本発明の方法におけるゲル過工程は、前記ニ
ーム樹皮熱水抽出液をゲル過剤を充填したカラ
ムにかけ、溶離する多糖体画分から分子量約
94000の多糖体を常法により採取することによつ
て実施される。ゲル過は、分画分子量が約8×
105以下のゲル過剤を用いて行なわれ、所望の
多糖体は、最初の画分から採取される。
上記工程で使用されるゲル過剤としては、デ
キストランゲル、ポリアクリルアミドゲル、ポリ
ビニル系のポリマーゲル、多孔性ガラスビーズ等
があげられる。これらは、例えばセフアデツクス
G−100、G−200、セフアクリルS−300(以上フ
アルマシア社製品、スエーデン)、バイオゲルP
−100〜P−300(バイオラツド社製品、米国)、ト
ヨパールHW−50、HW−55(東洋曹達工業、日
本)、CPG−10(エレクトロ・ヌクレオニツクス
社、米国)等の製品名で市販されている。さら
に、本発明の方法においては、分画分子量の異な
るゲル過剤を組合せて使用することにより所望
の多糖体を高純度で単離することができる。即
ち、ニーム樹皮熱水抽出液を分画分子量約1×
103〜1×105乃至1×103〜2×105のゲル過剤
(例えばセフアデツクスG−100、G−200、バイ
オゲルP−100、トヨパールHW−50等)を充填
したカラムにかけ蒸留水で溶離すると多糖体が3
つの画分に分画される。最初に溶出する画分を採
取し、これを分画分子量約1×103〜2×105乃至
1×103〜8×105のゲル過剤(例えばセフアデ
ツクスG−200、セフアクリルS−300、バイオゲ
ルP−300、トヨパールHW−60等)を充填した
カラムにかけ蒸留水で溶離すると多糖体がさらに
2つの画分に分画される。最初に溶出する画分を
採取し、蒸留乾固または凍結乾燥すると目的とす
る抗腫瘍性多糖体が得られる。かくして得られた
多糖体は次の構造および特性を有する。
(イ) 構造
α−(1→4)−グルカンの主鎖にアラビノー
スがα−(1→6)結合し、グルコースとアラ
ビノースの構成割合が約5:1の中性多糖体。
(ロ) 色と形状
凍結乾燥品は白色粉末である。
(ハ) 溶解性
水に可溶で、メタノール、エタノール、アセ
トン、エーテル、クロロホルム、酢酸エチル、
ベンゼンおよびヘキサン等の有機溶媒に不溶で
ある。
(ニ) 呈色反応
フエノール硫酸反応、アンスロン硫酸反応に
陽性でヨウ素の添加により青緑色を呈する。
(ホ) 分子量
分画分子量1×103〜2×105の分子篩剤を用
いたカラムゲルクロマトグラフイで単一のピー
クを与え、分子量は約94000である。
(ヘ) 比旋光度
〔α〕22 D:−35゜(c=0.4、H2O)
(ト) 赤外線吸収スペクトル
第1図に示す通りである。
IRνKBr naxcm-1:3400、2930、1620
(チ) 紫外線吸収スペクトル
水溶液中の測定で吸収極大を示さず、末端吸
収のみを示す。
(リ) 13C核磁気共鳴スペクトル
重水中で外部基準にTMS(テトラメチルシラ
ン)を使用して測定した100MHz 13C核磁気共
鳴スペクトルは第2図の通りである。
δppm:108.9、101.1、74.8、72.9、62.1
本発明の多糖体は、薬理試験の結果、ザルコー
マ180腹水型および固形型マウス移植腫瘍に対し
て顕著な阻止作用を有することが確認された。次
にその試験例を示す。
試験例 1
ザルコーマ180腹水ガンに対する効果
(試料調製)
リン酸緩衝食塩水(ギブコ社製、リン酸
9.5mMを含む;PBS)に0.5%カルボキシメチル
セルロース(CMC)を懸濁させた溶液に所定濃
度になるように試料を溶解させた。
(ザルコーマ180ガン細胞移植)
ICRマウス腹腔中で継代培養したザルコーマ
180ガン細胞を腹水とともにとり出し、生理食塩
水で適当に希釈して細胞数が1.0×108個/mlとな
るように調製した。この細胞懸濁液の0.1mlを4
週令雄ICRマウス腹腔へ注射器を用いて移植し
た。従つて1匹あたりの移植細胞数は1.0×107個
である。
(試料投与)
ザルコーマ180ガン細胞を移植した次の日より
1日1回連続4日間、上に調製した試料を注射器
を用いて腹腔に0.1ml投与した。1試料1濃度に
つき6匹のマウスを使用した。対照は試料の溶剤
として用いた上記CMC入りPBSを同様に投与し
たものとした。投与量の表示はマウス体重1Kgあ
たりのmg数とした。
(効果の判定法)
ガン細胞移植後7日目にそれぞれのマウスの体
重を測定した。次に腹腔に貯まつた腹水を全量と
り出した後のマウスの体重を測定した。腹水採取
前後の体重の差を腹水量とする。採取した腹水を
ヘマトクリツト管に吸い込ませ、ヘマトクリツト
測定用ローターを用いて、低温で遠心分離し、血
液のヘマトクリツト値に相当するアサイトクリツ
ト値を得た(腹水中に占めるガン細胞の割合)。
腹水量にこの値を乗ずれば全腹水中の細胞の容量
が得られる。これを全細胞容量(トータル・パツ
クト・セル・ボリユウム;TPCV)とする。対照
では、全腹水量は6〜10ml、TPCVは、1.6〜2.5
mlとなつた。
試料投与マウスのTPCVと対照投与マウスの
TPCVの比(T/C)をとつて100〜66%のもの
をガンに対する効果なし(−)、65〜41%のもの
をやや有効(+)、40〜11%のものを有効()、
10〜0%のものを著効()とする。結果を表1
に示す。
試験例 2
ザルコーマ180固型ガンに対する効果
(ザルコーマ180ガン細胞移植)
試験例と同様にして1.0×108個/mlの細胞懸濁
液を調製した。この懸濁液の0.1mlを4週令、雄
ICRマウス背部皮下に注射器を用いて細胞を移植
した。
(効果判定法)
ガン細胞移植後21日目に成長したガン組織を摘
出し、その重量を測定した(1群6匹の平均値)。
この重量と対照のものとの比(T/C)をとつて
効果判定を行つた。対照のガン組織重量は3.0〜
4.5gであつた。比の値が100〜71%のものを無効
(−)、70〜51%のものをやや有効(+)、50〜21
%のものを有効()、20〜0%のものを著効
()とした。結果を表1に示す。
表1から明らかなように、本発明の多糖体は、
ザルコーマ180移植ガンのうち、特に腹水ガンに
対して強い抑制効果を有している。DETAILED DESCRIPTION OF THE INVENTION BACKGROUND OF THE INVENTION Technical Field The present invention relates to a novel antitumor polysaccharide and a method for producing the same. More specifically, the present invention relates to an antitumor neutral polysaccharide obtained by purifying a hot water extract of neem bark, and a method for producing the same. The polysaccharide of the present invention is useful as a therapeutic agent for cancer. Prior Art It has been known that neem extracts have various pharmacological actions. Namely, neem bark, leaves,
A method for obtaining skin cosmetics by extracting flowers, fruits, branches, root bark, or resin with water or a hydrophilic solvent, or by pulverizing them (Japanese Patent Publications No. 52-28853, No. 52-28854)
and 53-10125), a method for extracting the above neem raw material with a hydrophilic solvent and/or hot water to obtain a component having antibacterial effects and gastrointestinal/liver function improving effects (Japanese Patent Publication No. 53-10124); Method for obtaining ingredients effective for the treatment of skin diseases and rheumatism by extraction with hydrophobic solvents (Special Publication No. 13689, 1983)
has been reported. The present inventors previously discovered that a hot water extract of neem bark has cell division inhibiting activity, but as a result of further research, it was found that α-(1→ 4) A neutral polysaccharide in which arabinose is α-(1→6) linked to the main chain of glucan and the composition ratio of glucose and arabinose is approximately 5:1 was isolated. This polysaccharide is a new compound that has not been described in any literature and has excellent antitumor effects. OBJECT OF THE INVENTION Therefore, an object of the present invention is to provide the above polysaccharide useful as an anticancer agent. As described below, the polysaccharide of the present invention exhibits strong inhibitory activity against Sarcoma 180 ascites type and solid mouse transplanted tumors, and is particularly effective against established solid tumors. A further object of the present invention is to provide a method for producing the above polysaccharide. According to the method of the present invention, the polysaccharide is produced by treating a hot water extract of neem bark with a molecular sieve, particularly gel filtration, and collecting a compound having a molecular weight of about 94,000. DETAILED DESCRIPTION OF THE INVENTION The present invention first consists of an antitumor polysaccharide obtained from neem bark and having the following structure and properties. (a) Structure A neutral polysaccharide in which α-(1→6) arabinose is bonded to the main chain of α-(1→4)-glucan, and the composition ratio of glucose and arabinose is approximately 5:1. (b) Color and shape The freeze-dried product is a white powder. (c) Solubility Soluble in water, methanol, ethanol, acetone, ether, chloroform, ethyl acetate,
Insoluble in organic solvents such as benzene and hexane. (d) Color reaction It is positive for the phenol sulfuric acid reaction and the anthrone sulfuric acid reaction, and exhibits a bluish-green color when iodine is added. (e) Molecular weight A single peak is obtained by column gel chromatography using a molecular sieve with a molecular weight cutoff of 1×10 3 to 2×10 5 , and the molecular weight is about 94,000. (f) Specific rotation [α] 22 D : -35° (c=0.4, H 2 O) (g) Infrared absorption spectrum As shown in Figure 1. IRν KBr nax cm -1 : 3400, 2930, 1620 (H) Ultraviolet absorption spectrum When measured in an aqueous solution, it does not show an absorption maximum, but shows only terminal absorption. (li) 13 C nuclear magnetic resonance spectrum The 100MHz 13 C nuclear magnetic resonance spectrum measured in heavy water using TMS (tetramethylsilane) as an external standard is shown in Figure 2. δppm: 108.9, 101.1, 74.8, 72.9, 62.1 Second, the present invention provides a method for producing the above-mentioned antitumor polysaccharide, which comprises treating a hot water extract of neem bark with a molecular sieve and collecting a compound having a molecular weight of about 94,000. Consisting of Thirdly, the present invention provides the above-mentioned molecular sieve treatment to first reduce the molecular weight cut-off from about 1×10 3 to 1×10 5 to 1×10 3 to 2×
10 5 molecular sieve, and then the first polysaccharide fraction was further reduced to a molecular weight cut-off of approximately 1×10 3 to 2×10 5 .
The above-mentioned method for producing an antitumor polysaccharide is performed by using a molecular sieve of 1×10 3 to 8×10 5 and collecting the first polysaccharide fraction. Fourthly, the present invention comprises a method for producing the antitumor polysaccharide, wherein the molecular sieve treatment is gel filtration, and the molecular sieve agent is a gel filtration agent. A fifth aspect of the present invention comprises a method for producing the antitumor polysaccharide, wherein the gelling agent is dextran gel, polyacrylamide gel, hydrophilic polyvinyl gel, or porous glass beads. When carrying out the method of the present invention, a hot water extract of neem bark is subjected to molecular sieve treatment, in particular gel filtration,
A compound with a molecular weight of approximately 94,000 is collected. Neem, which is a raw material plant for the method of the present invention, has a scientific name of Melia azadirachta, and is a woody plant that grows naturally in tropical regions and reaches a height of 10 m or more. In the method of the present invention, a hot water extract of neem bark is used as a raw material. The extraction treatment of neem bark with hot water is carried out according to a conventional method. That is, it is carried out by adding hot water to shredded neem bark, or by adding water to neem bark and heating the mixture to boiling. Heating can be carried out in a boiling water bath or over an open fire. The extraction time is appropriately determined depending on the quality of the raw materials, etc., but is usually 1 to 48 hours. After the extraction is complete,
An extract is obtained by filtering the extraction mixture. Since the neem bark hot water extract thus obtained contains a large amount of impurities, it is desirable to purify the extract by alcohol precipitation or dialysis membrane method before subjecting it to the gel filtration step of the present invention. . For example, when purifying by alcohol precipitation, an alcohol such as methanol or ethanol is added to the above extract, and the resulting precipitate is collected by a conventional method, for example, by centrifugation. When purifying by dialysis membrane method, put the extract into a dialysis membrane,
The dialyzed solution is dialyzed against water, and the dialyzed solution is concentrated to dryness or freeze-dried, as desired, to obtain an extract. Dialysis membranes with a molecular weight cutoff of 50,000 or less, such as Spectra Pore 1-6 (products of Spectrum Medical Industries), Visking
Tube (a product of Union Carbide) is used. The extract obtained by purification by alcohol precipitation method or dialysis membrane method is dissolved in water to obtain a hot water extract of neem bark, which is a raw material for the method of the present invention. moreover,
Prior to the hot water extraction treatment of neem bark, it is also desirable to pre-extract neem bark with an organic solvent and/or water at room temperature to remove unnecessary components. Solvents used for extraction pretreatment include methanol, ethanol, propanol,
Examples include polar organic solvents such as pyridine and acetone, and non-polar organic solvents such as benzene, toluene, xylene, n-hexane, chloroform, carbon tetrachloride, and ethyl acetate. In the gel filtration step in the method of the present invention, the neem bark hot water extract is applied to a column packed with a gelling agent, and the eluted polysaccharide fraction has a molecular weight of approximately
It is carried out by collecting 94,000 polysaccharides using a conventional method. Gel filtration has a molecular weight cut-off of approximately 8×
It is carried out using up to 10 5 gelling agents and the desired polysaccharide is collected from the first fraction. Examples of the gelling agent used in the above step include dextran gel, polyacrylamide gel, polyvinyl polymer gel, and porous glass beads. These include, for example, Cephadex G-100, G-200, Cephacryl S-300 (products of Pharmacia, Sweden), Biogel P
-100~P-300 (Biorad Inc., USA), Toyopearl HW-50, HW-55 (Toyo Soda Kogyo, Japan), CPG-10 (Electro Nucleonics, USA), etc. ing. Furthermore, in the method of the present invention, a desired polysaccharide can be isolated with high purity by using a combination of gelling agents having different molecular weight cutoffs. That is, the neem bark hot water extract has a molecular weight cut-off of approximately 1×
Distilled water was poured into a column packed with 10 3 to 1 x 10 5 to 1 x 10 3 to 2 x 10 5 gelling agents (e.g., Cephadex G-100, G-200, Biogel P-100, Toyopearl HW-50, etc.). When eluted with
It is fractionated into two fractions. The first eluted fraction is collected and mixed with a gel filter having a molecular weight cut-off of approximately 1×10 3 to 2×10 5 to 1×10 3 to 8×10 5 (e.g. Cephadex G-200, Cephacryl S-300). , Biogel P-300, Toyopearl HW-60, etc.) and eluted with distilled water, the polysaccharide is further fractionated into two fractions. The first eluted fraction is collected and distilled to dryness or freeze-dried to obtain the desired antitumor polysaccharide. The polysaccharide thus obtained has the following structure and properties. (a) Structure A neutral polysaccharide in which arabinose is α-(1→6) linked to the main chain of α-(1→4)-glucan, and the composition ratio of glucose and arabinose is approximately 5:1. (b) Color and shape The freeze-dried product is a white powder. (c) Solubility Soluble in water, methanol, ethanol, acetone, ether, chloroform, ethyl acetate,
Insoluble in organic solvents such as benzene and hexane. (d) Color reaction It is positive for the phenol sulfuric acid reaction and the anthrone sulfuric acid reaction, and exhibits a bluish-green color when iodine is added. (E) Molecular Weight A single peak is obtained by column gel chromatography using a molecular sieve with a molecular weight cutoff of 1×10 3 to 2×10 5 , and the molecular weight is approximately 94,000. (f) Specific rotation [α] 22 D : -35° (c=0.4, H 2 O) (g) Infrared absorption spectrum As shown in Figure 1. IRν KBr nax cm -1 : 3400, 2930, 1620 (h) Ultraviolet absorption spectrum When measured in an aqueous solution, it does not show an absorption maximum, but shows only terminal absorption. (li) 13 C nuclear magnetic resonance spectrum The 100MHz 13 C nuclear magnetic resonance spectrum measured in heavy water using TMS (tetramethylsilane) as an external standard is shown in Figure 2. δppm: 108.9, 101.1, 74.8, 72.9, 62.1 As a result of a pharmacological test, it was confirmed that the polysaccharide of the present invention has a remarkable inhibitory effect on Sarcoma 180 ascites type and solid mouse transplanted tumor. Next, a test example will be shown. Test example 1 Effect on Sarcoma 180 ascites cancer (sample preparation) Phosphate buffered saline (manufactured by Gibco, phosphoric acid
The sample was dissolved in a solution of 0.5% carboxymethylcellulose (CMC) suspended in PBS containing 9.5mM to a predetermined concentration. (Sarcoma 180 cancer cell transplantation) Sarcoma subcultured in the peritoneal cavity of ICR mice
180 cancer cells were taken out together with ascites fluid and diluted appropriately with physiological saline so that the number of cells was 1.0 x 10 8 cells/ml. 4 0.1 ml of this cell suspension
It was transplanted into the abdominal cavity of a week-old male ICR mouse using a syringe. Therefore, the number of transplanted cells per animal was 1.0×10 7 cells. (Sample Administration) Starting from the next day after transplanting the Sarcoma 180 cancer cells, 0.1 ml of the sample prepared above was administered once a day for 4 consecutive days using a syringe into the abdominal cavity. Six mice were used per sample per concentration. As a control, the above-mentioned PBS containing CMC, which was used as a solvent for the sample, was administered in the same manner. The dosage was expressed as mg per kg of mouse body weight. (Method for determining efficacy) The weight of each mouse was measured on the 7th day after cancer cell transplantation. Next, the weight of the mouse was measured after removing the entire amount of ascites that had accumulated in the abdominal cavity. The difference in body weight before and after ascites collection is considered the amount of ascites. The collected ascitic fluid was sucked into a hematocrit tube and centrifuged at low temperature using a hematocrit measuring rotor to obtain an acytocrit value, which corresponds to the hematocrit value of blood (percentage of cancer cells in ascites).
Multiplying the amount of ascites by this value gives the volume of cells in the total ascites. This is defined as the total cell volume (TPCV). In controls, the total ascitic fluid volume was 6-10 ml, and the TPCV was 1.6-2.5.
It became ml. TPCV of sample-treated mice and control-treated mice
Taking the TPCV ratio (T/C), those with 100-66% are not effective against cancer (-), those with 65-41% are somewhat effective (+), those with 40-11% are effective (),
10% to 0% is considered significant (). Table 1 shows the results.
Shown below. Test Example 2 Effect on Sarcoma 180 Solid Cancer (Sarcoma 180 Cancer Cell Transplantation) A cell suspension of 1.0×10 8 cells/ml was prepared in the same manner as in Test Example. Add 0.1 ml of this suspension to a 4-week-old male
Cells were transplanted subcutaneously into the back of ICR mice using a syringe. (Efficacy evaluation method) Cancer tissue that had grown on the 21st day after cancer cell transplantation was removed and its weight was measured (average value of 6 animals per group).
The effect was determined by determining the ratio (T/C) between this weight and that of the control. Control cancer tissue weight is 3.0 ~
It was 4.5g. Ratio values of 100 to 71% are invalid (-), ratios of 70 to 51% are slightly valid (+), 50 to 21
% was considered effective (), and 20% to 0% was considered markedly effective (). The results are shown in Table 1. As is clear from Table 1, the polysaccharide of the present invention is
Sarcoma 180 has a particularly strong suppressive effect on ascites cancer among transplanted cancers.
【表】
試験例 3
定着固形ガンに対する効果
ザルコーマ180細胞1×107個を雄性ICRマウス
(5匹)背部皮下に移植し、飼育した。固形腫瘍
が完全に定着し、1〜2g程の大きさとなつた10
日目から1日1回、5日間マウス腹腔内に所定量
の試料を投与した。移植後21日目に腫瘍部を切り
とりその重量部を対照群と比較し、試験例2の方
法に従つて効果を判定した。結果を表2に示す。[Table] Test Example 3 Effect on established solid tumors 1 x 10 7 Sarcoma 180 cells were subcutaneously transplanted into the backs of male ICR mice (5 mice) and raised. The solid tumor was completely established and the size was about 1 to 2 g.10
A predetermined amount of the sample was intraperitoneally administered to the mouse once a day for 5 days. On the 21st day after transplantation, the tumor part was cut out and its weight was compared with that of the control group, and the efficacy was determined according to the method of Test Example 2. The results are shown in Table 2.
【表】
試験例 4
急性毒性
本発明の多糖体を体重20±1gのICR雄性マウス
に投与して急性毒性試験を行なつた結果、LD50
値は、腹腔内投与で600mg/Kg以上、経口投与で
は1000mg/Kg以上であつた。
上記の薬理試験の結果からも明らかなように、
本発明の多糖体は顕著な抗腫瘍性を有し、毒性は
極めて低いので、制癌剤として優れた性質を有す
る。また、定着固形ガンに対して特に強い抑制効
果を有することから本発明の多糖体は免疫賦活型
の抗腫瘍作用を有すると考えられる。
本発明の多糖体は、各種の癌疾患に対して有効
であり、投与量は、症状、年令、体重などによつ
て異なるが、通常は成人に対して1日100〜2500
mgであり、1〜4回に分けて投与することができ
る。
本発明の多糖体は任意所要の製剤用担体または
賦形剤を用いて経口または非経口投与用に製剤化
される。
経口投与用の錠剤、散剤、カプセル剤、顆粒剤
等は慣用の賦形剤例えば炭酸カルシウム、リン酸
カルシウム、とうもろこしでんぷん、馬鈴薯でん
ぷん、砂糖、ラクトース、タルク、ステアリン酸
マグネシウム、アラビアゴム等を含有していても
よい。経口投与用液体製剤は水性または油性懸濁
液、溶液、シロツプ、エリキシル剤その他であつ
てもよい。
注射用製剤は溶液または懸濁液の形態であり、
懸濁化剤、安定剤または分散剤のような処方剤を
含んでいてもよく、滅菌蒸留水、精油たとえばピ
ーナツツ油、とうもろこし油あるいは非水溶媒、
ポリエチレングリコール、ポリプロピレングリコ
ール等を含有していてもよい。
直腸内投与のためには坐剤用組成物の形で提供
され、周知の製剤担体たとえばポリエチレングリ
コール、ラノリン、ココナツト油等を含有してい
てもよい。
次に参考例および実施例を示して本発明をさら
に具体的に説明する。
参考例
ニーム樹皮熱水抽出液の製造
(1) ニーム樹皮乾燥品50gをベンゼン(500ml×
3)およびメタノール(500ml×3)を用いて
室温で24時間抽出前処理し、得られた抽出残渣
を熱水200mlで3回抽出処理した。得られた抽
出液を合し、ロータリーエバポレーターで濃縮
乾固し、1960.5mgの粉末を得た。
(2) 上記(1)で得られた粉末1000mgを水200mlに溶
解し、得られた水溶液に純エタノールを撹拌し
ながら室温で徐々に加え、水溶液中のエタノー
ル濃度が80%になつたときに添加をやめ、生成
した沈澱を遠心分離により採取し、594.5mgの
褐色粉末を得た。
(3) 上記(1)で得られた粉末500mgを水50mlにとか
し、この水溶液をスペクトラ ポア6(分画分
子量50000)に入れ、水に対して透析した。透
析内液をロータリーエバポレーターを用いて濃
縮乾固して褐色の粉末310mgを得た。
実施例
上記参考例(2)または(3)で得られたニーム樹皮熱
水抽出物1020mgを20mlの蒸留水に溶解し、セフア
デツクスG−100を充填したカラム(直径7.0cm、
長さ35.0cm)に注ぎ、蒸留水を用いてゲル過を
行つた。フエノール硫酸法で溶出液中の糖含量を
定量しつつゲル過を行うと、多糖体は3つに分
画される。最初に溶出する画分から多糖体273mg
が得られる。次にこの50mgを5mlの蒸留水に溶解
し、セフアデツクスG−200を充填したカラム
(直径4.0cm、長さ50.0cm)に注ぎ、蒸留水を用い
てゲル過を行つた。フエノール硫酸法で溶出液
中の糖含量を定量しつつゲル過を行うと多糖体
は2つに分画される。最初に溶出する多糖体画分
より所望の抗腫瘍性多糖体18mgが得られた。この
ものは、高速液体クロマトおよび電気泳動で単一
の化合物であることを確認した。
また上記ゲル過において、セフアデツクスG
−200の代りにセフアクリルS−300を使用しても
同様の結果が得られた。
発明の具体的効果
上に詳述した如く、本発明によれば、第1に、
抗腫瘍性多糖体が提供される。本多糖体は文献未
載の新規化合物であつて、試験例で示したよう
に、ザルコーマ180腹水型および固形型マウス移
植腫瘍等に対して強い抑制活性を示し、毒性は非
常に低いので、制癌剤として有用である。
本発明によれば、第2に、上記多糖体の製造法
が提供される。即ち、該多糖体は、ニーム樹皮の
熱水抽出液を分子篩処理し、分子量約94000を有
する化合物を採取することによつて得られる。
本発明によれば、第3に、上記多糖体の有利な
製造法が提供される。即ち、該多糖体は、上記分
子篩処理を分画分子量約1×103〜1×105乃至1
×103〜2×105の分子篩剤と分画分子量約1×
103〜2×105〜8×105の分子篩剤と組合せて行
なうことによつて高純度で得られる。
本発明によれば、第4に、上記多糖体のさらに
有利な製造法が提供される。即ち、該多糖体は、
上記分子篩処理としてゲル過剤を用いたゲル
過を行うことによつてより容易に得られる。
本発明によれば、第5に、上記多糖体のさらに
有利な製造法が提供される。即ち、該多糖体は、
ゲル過剤としてデキストランゲル、ポリアクリ
ルアミドゲル、親水性ポリビニル系ゲルまたは多
孔性ガラスビーズを使用することによつて容易に
高純度で得られる。[Table] Test Example 4 Acute Toxicity An acute toxicity test was conducted by administering the polysaccharide of the present invention to ICR male mice weighing 20±1 g. As a result, LD 50
The values were 600 mg/Kg or more for intraperitoneal administration and 1000 mg/Kg or more for oral administration. As is clear from the results of the pharmacological tests mentioned above,
The polysaccharide of the present invention has remarkable antitumor properties and extremely low toxicity, so it has excellent properties as an anticancer agent. Furthermore, since it has a particularly strong suppressive effect on established solid cancers, the polysaccharide of the present invention is considered to have an immunostimulatory antitumor effect. The polysaccharide of the present invention is effective against various cancer diseases, and the dosage varies depending on symptoms, age, body weight, etc., but is usually 100 to 2,500 doses per day for adults.
mg, and can be administered in 1 to 4 divided doses. The polysaccharides of the present invention are formulated for oral or parenteral administration using any required pharmaceutical carriers or excipients. Tablets, powders, capsules, granules, etc. for oral administration contain conventional excipients such as calcium carbonate, calcium phosphate, corn starch, potato starch, sugar, lactose, talc, magnesium stearate, gum arabic, etc. Good too. Liquid preparations for oral administration may be aqueous or oily suspensions, solutions, syrups, elixirs, and the like. Injectable preparations are in the form of solutions or suspensions;
It may contain formulation agents such as suspending, stabilizing or dispersing agents, sterile distilled water, essential oils such as peanut oil, corn oil or non-aqueous solvents;
It may contain polyethylene glycol, polypropylene glycol, etc. For rectal administration, they may be provided in the form of suppository compositions and may contain well-known pharmaceutical carriers such as polyethylene glycol, lanolin, coconut oil, and the like. Next, the present invention will be explained in more detail with reference to Reference Examples and Examples. Reference example Production of neem bark hot water extract (1) 50g of dried neem bark was mixed with benzene (500ml x
3) and methanol (500 ml x 3) at room temperature for 24 hours, and the resulting extraction residue was extracted three times with 200 ml of hot water. The obtained extracts were combined and concentrated to dryness using a rotary evaporator to obtain 1960.5 mg of powder. (2) Dissolve 1000 mg of the powder obtained in (1) above in 200 ml of water, gradually add pure ethanol to the resulting aqueous solution at room temperature while stirring, and when the ethanol concentration in the aqueous solution reaches 80%. The addition was stopped, and the formed precipitate was collected by centrifugation to obtain 594.5 mg of brown powder. (3) 500 mg of the powder obtained in (1) above was dissolved in 50 ml of water, and this aqueous solution was poured into Spectra Pore 6 (molecular weight cut off: 50,000) and dialyzed against water. The dialyzed fluid was concentrated to dryness using a rotary evaporator to obtain 310 mg of brown powder. Example 1020 mg of the neem bark hot water extract obtained in Reference Example (2) or (3) above was dissolved in 20 ml of distilled water, and a column (diameter 7.0 cm,
(length 35.0 cm) and gel filtration was performed using distilled water. When gel filtration is performed while quantifying the sugar content in the eluate using the phenol-sulfuric acid method, the polysaccharide is fractionated into three parts. 273 mg of polysaccharide from the first eluting fraction
is obtained. Next, 50 mg of this solution was dissolved in 5 ml of distilled water, poured into a column (diameter 4.0 cm, length 50.0 cm) packed with Cephadex G-200, and gel filtration was performed using distilled water. When gel filtration is performed while quantifying the sugar content in the eluate using the phenol-sulfuric acid method, the polysaccharide is fractionated into two. 18 mg of the desired antitumor polysaccharide was obtained from the first eluted polysaccharide fraction. This compound was confirmed to be a single compound by high performance liquid chromatography and electrophoresis. In addition, in the above gel filtration, Cephadex G
Similar results were obtained when Cephacryl S-300 was used instead of -200. Specific Effects of the Invention As detailed above, according to the present invention, firstly,
Anti-tumor polysaccharides are provided. This polysaccharide is a new compound that has not been described in any literature, and as shown in the test examples, it shows strong inhibitory activity against Sarcoma 180 ascites type and solid mouse transplanted tumors, etc., and has very low toxicity, so it can be used as an anticancer agent. It is useful as According to the present invention, secondly, a method for producing the above polysaccharide is provided. That is, the polysaccharide is obtained by treating a hot water extract of neem bark with a molecular sieve and collecting a compound having a molecular weight of about 94,000. According to the present invention, thirdly, an advantageous method for producing the above polysaccharide is provided. That is, the polysaccharide undergoes the above molecular sieve treatment to have a molecular weight cut-off of approximately 1×10 3 to 1×10 5 to 1
×10 3 to 2 × 10 5 molecular sieve and molecular weight cutoff approximately 1 ×
High purity can be obtained by carrying out the process in combination with a molecular sieve of 10 3 to 2×10 5 to 8×10 5 . According to the present invention, fourthly, a more advantageous method for producing the above polysaccharide is provided. That is, the polysaccharide is
It can be obtained more easily by performing gel filtration using a gel filtration agent as the molecular sieve treatment. According to the present invention, fifthly, a more advantageous method for producing the above polysaccharide is provided. That is, the polysaccharide is
High purity can be easily obtained by using dextran gel, polyacrylamide gel, hydrophilic polyvinyl gel or porous glass beads as a gelling agent.
第1図は本発明の抗腫瘍性多糖体の赤外線吸収
スペクトルを示し、第2図は、同物質の 13C核磁
気共鳴スペクトルを示す。
FIG. 1 shows the infrared absorption spectrum of the antitumor polysaccharide of the present invention, and FIG. 2 shows the 13 C nuclear magnetic resonance spectrum of the same substance.
Claims (1)
を有する抗腫瘍性多糖体。 (イ) 構造 α−(1→4)−グルカンの主鎖にアラビノー
スがα−(1→6)結合し、グルコースとアラ
ビノースの構成割合が約5:1の中性多糖体。 (ロ) 色と形状 凍結乾燥品は白色粉末である。 (ハ) 溶解性 水に可溶で、メタノール、エタノール、アセ
トン、エーテル、クロロホルム、酢酸エチル、
ベンゼンおよびヘキサン等の有機溶媒に不溶で
ある。 (ニ) 呈色反応 フエノール硫酸反応、アンスロン硫酸反応に
陽性でヨウ素の添加により青緑色を呈する。 (ホ) 分子量 分画分子量1×103〜2×105の分子篩剤を用
いたカラムゲルクロマトグラフイにより単一の
ピークを与え、分子量は約94000である。 (ヘ) 比旋光度 〔α〕22 D:−35゜(c=0.4、H2O) (ト) 赤外線吸収スペクトル 第1図に示す通りである。 IRνKBr naxcm-1:3400、2930、1620 (チ) 紫外線吸収スペクトル 水溶液中の測定で吸収極大を示さず、末端吸
収のみを示す。 (リ) 13C核磁気共鳴スペクトル 重水中で外部基準にTMS(テトラメチルシラ
ン)を使用して測定した100MHz 13C核磁気共
鳴スペクトルは第2図の通りである。 δppm:108.9、101.1、74.8、72.9、62.1 2 ニーム樹皮の熱水抽出液を分子篩処理し、分
子量約94000を有する化合物を採取することを特
徴とする下記構造および特性を有する抗腫瘍性多
糖体の製造法。 (イ) 構造 α−(1→4)−グルカンの主鎖にアラビノー
スがα−(1→6)結合し、グルコースとアラ
ビノースの構成割合が約5:1の中性多糖体。 (ロ) 色と形状 凍結乾燥品は白色粉末である。 (ハ) 溶解性 水に可溶で、メタノール、エタノール、アセ
トン、エーテル、クロロホルム、酢酸エチル、
ベンゼンおよびヘキサン等の有機溶媒に不溶で
ある。 (ニ) 呈色反応 フエノール硫酸反応、アンスロン硫酸反応に
陽性でヨウ素の添加により青緑色を呈する。 (ホ) 分子量 分画分子量1×103〜2×105の分子篩剤を用
いたカラムゲルクロマトグラフイにより単一の
ピークを与え、分子量は約94000である。 (ヘ) 比旋光度 〔α〕22 D:−35゜(c=0.4、H2O) (ト) 赤外線吸収スペクトル 第1図に示す通りである。 IRνKBr naxcm-1:3400、2930、1620 (チ) 紫外線吸収スペクトル 水溶液中の測定で吸収極大を示さず、末端吸
収のみを示す。 (リ) 13C核磁気共鳴スペクトル 重水中で外部基準にTMS(テトラメチルシラ
ン)を使用して測定した100MHz 13C核磁気共
鳴スペクトルは第2図の通りである。 δppm:108.9、101.1、74.8、72.9、62.1 3 上記分子篩処理は、先ず分画分子量約1×
103〜1×105乃至1×103〜2×105の分子篩剤を
用いて行ない、次いで最初の多糖体画分をさらに
分画分子量約1×103〜2×105乃至1×103〜8
×105の分子篩剤を用いて行ない、最初の多糖体
画分を採取することを特徴とする特許請求の範囲
第2項記載の抗腫瘍性多糖体の製造法。 4 上記分子篩処理がゲル過であり、上記分子
篩剤がゲル過剤である特許請求の範囲第2項ま
たは第3項記載の抗腫瘍性多糖体の製造法。 5 上記ゲル過剤がデキストランゲル、ポリア
クリルアミドゲル、親水性ポリビニル系ゲルまた
は多孔性ガラスビーズである特許請求の範囲第4
項記載の抗腫瘍性多糖体の製造法。[Scope of Claims] 1. An antitumor polysaccharide obtained from neem bark and having the following structure and properties. (a) Structure A neutral polysaccharide in which α-(1→6) arabinose is bonded to the main chain of α-(1→4)-glucan, and the composition ratio of glucose and arabinose is approximately 5:1. (b) Color and shape The freeze-dried product is a white powder. (c) Solubility Soluble in water, methanol, ethanol, acetone, ether, chloroform, ethyl acetate,
Insoluble in organic solvents such as benzene and hexane. (d) Color reaction It is positive for the phenol sulfuric acid reaction and the anthrone sulfuric acid reaction, and exhibits a bluish-green color when iodine is added. (e) Molecular weight A single peak is obtained by column gel chromatography using a molecular sieve with a molecular weight cutoff of 1×10 3 to 2×10 5 , and the molecular weight is about 94,000. (f) Specific rotation [α] 22 D : -35° (c=0.4, H 2 O) (g) Infrared absorption spectrum As shown in Figure 1. IRν KBr nax cm -1 : 3400, 2930, 1620 (H) Ultraviolet absorption spectrum When measured in an aqueous solution, it does not show an absorption maximum, but shows only terminal absorption. (li) 13 C nuclear magnetic resonance spectrum The 100MHz 13 C nuclear magnetic resonance spectrum measured in heavy water using TMS (tetramethylsilane) as an external standard is shown in Figure 2. δppm: 108.9, 101.1, 74.8, 72.9, 62.1 2. An antitumor polysaccharide having the following structure and characteristics characterized by treating a hot water extract of neem bark with a molecular sieve and collecting a compound having a molecular weight of about 94,000. Manufacturing method. (a) Structure A neutral polysaccharide in which α-(1→6) arabinose is bonded to the main chain of α-(1→4)-glucan, and the composition ratio of glucose and arabinose is approximately 5:1. (b) Color and shape The freeze-dried product is a white powder. (c) Solubility Soluble in water, methanol, ethanol, acetone, ether, chloroform, ethyl acetate,
Insoluble in organic solvents such as benzene and hexane. (d) Color reaction It is positive for the phenol sulfuric acid reaction and the anthrone sulfuric acid reaction, and exhibits a bluish-green color when iodine is added. (e) Molecular weight A single peak is obtained by column gel chromatography using a molecular sieve with a molecular weight cutoff of 1×10 3 to 2×10 5 , and the molecular weight is about 94,000. (f) Specific rotation [α] 22 D : -35° (c=0.4, H 2 O) (g) Infrared absorption spectrum As shown in Figure 1. IRν KBr nax cm -1 : 3400, 2930, 1620 (H) Ultraviolet absorption spectrum When measured in an aqueous solution, it does not show an absorption maximum, but shows only terminal absorption. (li) 13 C nuclear magnetic resonance spectrum The 100MHz 13 C nuclear magnetic resonance spectrum measured in heavy water using TMS (tetramethylsilane) as an external standard is shown in Figure 2. δppm: 108.9, 101.1, 74.8, 72.9, 62.1 3 The above molecular sieve treatment first
10 3 -1×10 5 to 1×10 5 to 2×10 5 molecular sieves, and then the first polysaccharide fraction is further divided into molecular weight fractions of about 1×10 3 to 2×10 5 to 1× 10 3 ~ 8
3. The method for producing an antitumor polysaccharide according to claim 2, which is carried out using a molecular sieve of ×10 5 and collecting the first polysaccharide fraction. 4. The method for producing an antitumor polysaccharide according to claim 2 or 3, wherein the molecular sieving treatment is gel filtration, and the molecular sieving agent is a gel filtration agent. 5. Claim 4, wherein the gelling agent is dextran gel, polyacrylamide gel, hydrophilic polyvinyl gel, or porous glass beads.
The method for producing the antitumor polysaccharide described in Section 1.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57025440A JPS58144320A (en) | 1982-02-19 | 1982-02-19 | Antitumor polysaccharide and its preparation |
DE19833305047 DE3305047A1 (en) | 1982-02-19 | 1983-02-14 | POLYSACCHARIDES, THEIR PRODUCTION AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM |
US06/466,553 US4536496A (en) | 1982-02-19 | 1983-02-15 | Polysaccharides N9GI, their preparation and therapeutic compositions containing them |
GB08304461A GB2120265B (en) | 1982-02-19 | 1983-02-17 | Polysaccharides their preparation and therapeutic compositions containing them |
CH937/83A CH653349A5 (en) | 1982-02-19 | 1983-02-18 | POLYSACCHARIDES, THEIR PRODUCTION AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM. |
FR8302708A FR2522001B1 (en) | 1982-02-19 | 1983-02-18 | POLYSACCHARIDES, THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THESE PRODUCTS |
IT19655/83A IT1193678B (en) | 1982-02-19 | 1983-02-18 | Anticancer polysaccharide N9GI |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57025440A JPS58144320A (en) | 1982-02-19 | 1982-02-19 | Antitumor polysaccharide and its preparation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57212104A Division JPS58144322A (en) | 1982-02-19 | 1982-12-04 | Purified antitumor extract of bark of melia azadirachta and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58144320A JPS58144320A (en) | 1983-08-27 |
JPS6318961B2 true JPS6318961B2 (en) | 1988-04-20 |
Family
ID=12166055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57025440A Granted JPS58144320A (en) | 1982-02-19 | 1982-02-19 | Antitumor polysaccharide and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58144320A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0322657U (en) * | 1989-07-10 | 1991-03-08 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101226660B1 (en) * | 2009-06-19 | 2013-01-25 | 일동제약주식회사 | Composition for preventing or treating dementia comprising toosendanin or extracts of Melia azedarach(Melia toosendan) |
-
1982
- 1982-02-19 JP JP57025440A patent/JPS58144320A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0322657U (en) * | 1989-07-10 | 1991-03-08 |
Also Published As
Publication number | Publication date |
---|---|
JPS58144320A (en) | 1983-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4511559A (en) | Biologically active polysaccharide concentrates and process for production of preparates containing such substances | |
US4536496A (en) | Polysaccharides N9GI, their preparation and therapeutic compositions containing them | |
US4537774A (en) | Hot-water extracts of neem bark | |
CN109160954B (en) | Muskmelon eggplant acidic polysaccharide and purification method and application thereof | |
CN114805624B (en) | Cortex moutan polysaccharide and preparation method and application thereof | |
JPS6318961B2 (en) | ||
JPS6318962B2 (en) | ||
JPS6153336B2 (en) | ||
JPS6153337B2 (en) | ||
JPS6153326B2 (en) | ||
JPS6153330B2 (en) | ||
JPH0335295B2 (en) | ||
JPH0335294B2 (en) | ||
JPS6153328B2 (en) | ||
JPH0335293B2 (en) | ||
JPH07238030A (en) | Hypoglycemic agent | |
CN109678981A (en) | A kind of preparation method of safflower polysaccharide, product and application | |
JPH01275602A (en) | Polysaccharide and manufacture thereof | |
JPS6153327B2 (en) | ||
JPS5940135B2 (en) | Polymer polysaccharide based on 1-3 linked glucose having interferon-inducing activity and method for producing the same | |
JPS6153329B2 (en) | ||
JPS6042331A (en) | Production of polysaccharide n9gi | |
JPH0335291B2 (en) | ||
WO1981002577A1 (en) | Novel cundurango glycosides,process for their preparation,antineoplastic agent,and composition containing same | |
CN117209617A (en) | Arabinogalactan aldehyde acid glycan and preparation method and application thereof |